JP2019517589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517589A5 JP2019517589A5 JP2019516103A JP2019516103A JP2019517589A5 JP 2019517589 A5 JP2019517589 A5 JP 2019517589A5 JP 2019516103 A JP2019516103 A JP 2019516103A JP 2019516103 A JP2019516103 A JP 2019516103A JP 2019517589 A5 JP2019517589 A5 JP 2019517589A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- car
- dose
- subject
- expressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 122
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 52
- 239000000203 mixture Substances 0.000 claims 32
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 21
- 238000002659 cell therapy Methods 0.000 claims 20
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 18
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 18
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 18
- 238000000034 method Methods 0.000 claims 13
- 230000003211 malignant effect Effects 0.000 claims 12
- 238000002560 therapeutic procedure Methods 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000036210 malignancy Effects 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 229960000390 fludarabine Drugs 0.000 claims 7
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 7
- 238000002203 pretreatment Methods 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 3
- 229960001507 ibrutinib Drugs 0.000 claims 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 2
- 208000031404 Chromosome Aberrations Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 229940124291 BTK inhibitor Drugs 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- 229960001183 venetoclax Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021199037A JP2022033929A (ja) | 2016-06-06 | 2021-12-08 | 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 |
| JP2023189795A JP2023184646A (ja) | 2016-06-06 | 2023-11-07 | 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346547P | 2016-06-06 | 2016-06-06 | |
| US62/346,547 | 2016-06-06 | ||
| US201662417292P | 2016-11-03 | 2016-11-03 | |
| US62/417,292 | 2016-11-03 | ||
| US201662429737P | 2016-12-03 | 2016-12-03 | |
| US62/429,737 | 2016-12-03 | ||
| PCT/US2017/036231 WO2017214207A2 (en) | 2016-06-06 | 2017-06-06 | Methods for the treatment of b cell malignancies using adoptive cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199037A Division JP2022033929A (ja) | 2016-06-06 | 2021-12-08 | 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517589A JP2019517589A (ja) | 2019-06-24 |
| JP2019517589A5 true JP2019517589A5 (enExample) | 2020-07-16 |
| JP7139318B2 JP7139318B2 (ja) | 2022-09-20 |
Family
ID=59227902
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516103A Active JP7139318B2 (ja) | 2016-06-06 | 2017-06-06 | 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 |
| JP2021199037A Pending JP2022033929A (ja) | 2016-06-06 | 2021-12-08 | 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 |
| JP2023189795A Pending JP2023184646A (ja) | 2016-06-06 | 2023-11-07 | 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199037A Pending JP2022033929A (ja) | 2016-06-06 | 2021-12-08 | 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 |
| JP2023189795A Pending JP2023184646A (ja) | 2016-06-06 | 2023-11-07 | 養子細胞療法を用いてｂ細胞悪性腫瘍を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200016199A1 (enExample) |
| EP (1) | EP3463437A2 (enExample) |
| JP (3) | JP7139318B2 (enExample) |
| KR (3) | KR102540751B1 (enExample) |
| CN (1) | CN109562151A (enExample) |
| AU (1) | AU2017277396B2 (enExample) |
| BR (1) | BR112018074406A2 (enExample) |
| CA (1) | CA3024725A1 (enExample) |
| MA (1) | MA45341A (enExample) |
| MX (2) | MX2018014911A (enExample) |
| WO (1) | WO2017214207A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202104804PA (en) | 2014-10-20 | 2021-06-29 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| NZ733841A (en) | 2015-01-16 | 2024-01-26 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for ror1 |
| CN108699149B (zh) | 2016-02-02 | 2023-01-06 | 弗雷德哈钦森癌症中心 | 抗-ror1抗体及其用途 |
| MX2019005029A (es) * | 2016-11-03 | 2019-10-24 | Juno Therapeutics Inc | Terapia de combinación de una terapia de células t y un inhibidor de tirosina cinasa de bruton (btk). |
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| CA3053539A1 (en) | 2017-02-27 | 2018-08-30 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
| EP3595440A2 (en) | 2017-03-14 | 2020-01-22 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| CN111065410A (zh) | 2017-09-06 | 2020-04-24 | 弗雷德哈钦森癌症研究中心 | 用于改善过继细胞疗法的方法 |
| AU2018352984B2 (en) | 2017-10-18 | 2024-02-01 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| BR112020008638A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| US20210145882A1 (en) * | 2018-04-13 | 2021-05-20 | Fred Hutchinson Cancer Research Center | Methods for adoptive cell therapy targeting ror1 |
| US20210121466A1 (en) * | 2018-05-03 | 2021-04-29 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| US20210401887A1 (en) * | 2018-10-31 | 2021-12-30 | The Children's Hospital Of Philadelphia | T cells from lymphatic fluid for diagnostic and therapeutic use |
| MX2021005366A (es) | 2018-11-08 | 2021-09-10 | Juno Therapeutics Inc | Metodos y combinaciones para el tratamiento y modulacion de celulas t. |
| IL283298B2 (en) * | 2018-11-30 | 2025-03-01 | Juno Therapeutics Inc | Methods for dosing and treating B-cell malignancies with adoptive cell therapy |
| WO2020113194A2 (en) * | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| CN111825769B (zh) * | 2019-04-16 | 2022-03-25 | 上海科技大学 | 一种泛素化缺失的嵌合抗原受体及其用途 |
| AU2020307667A1 (en) * | 2019-06-27 | 2022-01-20 | Crispr Therapeutics Ag | Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer |
| AU2020395318A1 (en) * | 2019-12-06 | 2022-06-09 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating B cell malignancies |
| MX2022009041A (es) * | 2020-01-24 | 2022-10-07 | Juno Therapeutics Inc | Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva. |
| JP2023519098A (ja) * | 2020-02-12 | 2023-05-10 | ジュノー セラピューティクス インコーポレイテッド | Ｃｄ１９指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用 |
| AU2021276312A1 (en) * | 2020-05-18 | 2022-12-22 | Robert Sackstein | Compositions and methods for treatment of inflammatory disorders |
| CN116209461A (zh) * | 2020-06-05 | 2023-06-02 | 特沙公司 | Cd-30阳性癌症的治疗 |
| EP4171585A1 (en) * | 2020-06-26 | 2023-05-03 | CRISPR Therapeutics AG | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| JP2023546178A (ja) * | 2020-10-20 | 2023-11-01 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Ｃｄ１９を標的とする遺伝子操作されたｔ細胞を用いたｂ細胞悪性腫瘍の同種他家細胞療法 |
| RU2758126C1 (ru) * | 2021-04-02 | 2021-10-26 | федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации | Способ прогнозирования развития рецидива диффузной В-крупноклеточной лимфомы |
| WO2022226355A2 (en) * | 2021-04-23 | 2022-10-27 | Myeloid Therapeutics, Inc. | Compositions and methods for conditioning patients for cell therapy |
| WO2022254337A1 (en) * | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| WO2025006561A2 (en) * | 2023-06-27 | 2025-01-02 | Nkarta, Inc. | Methods for treatment using cd19-directed immunotherapies |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP3338895B1 (en) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| HRP20150400T1 (hr) * | 2008-11-07 | 2015-05-08 | Amgen Research (Munich) Gmbh | Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| ES2778701T3 (es) * | 2012-07-13 | 2020-08-11 | The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer | Gestión de toxicidad para la actividad antitumoral de CAR |
| PL2884999T3 (pl) * | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
-
0
- MA MA045341A patent/MA45341A/fr unknown
-
2017
- 2017-06-06 CA CA3024725A patent/CA3024725A1/en active Pending
- 2017-06-06 KR KR1020197000351A patent/KR102540751B1/ko active Active
- 2017-06-06 AU AU2017277396A patent/AU2017277396B2/en not_active Ceased
- 2017-06-06 JP JP2019516103A patent/JP7139318B2/ja active Active
- 2017-06-06 BR BR112018074406-9A patent/BR112018074406A2/pt unknown
- 2017-06-06 EP EP17733663.3A patent/EP3463437A2/en not_active Withdrawn
- 2017-06-06 US US16/307,462 patent/US20200016199A1/en not_active Abandoned
- 2017-06-06 CN CN201780046873.8A patent/CN109562151A/zh active Pending
- 2017-06-06 MX MX2018014911A patent/MX2018014911A/es unknown
- 2017-06-06 KR KR1020247007298A patent/KR20240036704A/ko active Pending
- 2017-06-06 KR KR1020237018556A patent/KR102644950B1/ko active Active
- 2017-06-06 WO PCT/US2017/036231 patent/WO2017214207A2/en not_active Ceased
-
2018
- 2018-11-30 MX MX2024000151A patent/MX2024000151A/es unknown
-
2021
- 2021-12-08 JP JP2021199037A patent/JP2022033929A/ja active Pending
-
2023
- 2023-11-07 JP JP2023189795A patent/JP2023184646A/ja active Pending
-
2025
- 2025-01-17 US US19/031,042 patent/US20250197471A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517589A5 (enExample) | ||
| JP7682820B2 (ja) | Ｃａｒの抗腫瘍活性のための毒性管理 | |
| Pianko et al. | Immune checkpoint blockade for hematologic malignancies: a review | |
| Hude et al. | The emerging role of immune checkpoint inhibition in malignant lymphoma | |
| Fong et al. | Anti–cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment | |
| JP2024059707A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| Honeychurch et al. | Immuno-regulatory antibodies for the treatment of cancer | |
| JP2024023318A (ja) | 二重特異性抗体の組成物及びその使用方法 | |
| Cabo et al. | Trial watch: immunostimulatory monoclonal antibodies for oncological indications | |
| JP2017530694A5 (enExample) | ||
| EP3548083A1 (en) | Methods for modulation of car-t cells | |
| WO2019084234A1 (en) | METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS | |
| Katsin et al. | CAR-T cell therapy for classical Hodgkin lymphoma | |
| US20190287013A1 (en) | Methods for determining dosing of a therapeutic agent and related treatments | |
| JP7704748B2 (ja) | 逐次抗ｃｄ１９治療 | |
| Lam et al. | Pharmacokinetics and pharmacodynamics of immunotherapy | |
| Kaşmer et al. | Resistance to chimeric antigen receptor T cells (CAR-T) | |
| HK40116181A (en) | Toxicity management for anti-tumor activity of cars | |
| HK40116181B (en) | Toxicity management for anti-tumor activity of cars | |
| Zhong et al. | 184 Two types of anti-TIGIT antibodies with distinct binding epitope and functional activities | |
| WO2025096517A1 (en) | Factors for optimizing immunotherapy efficacy | |
| HK40069741B (en) | Toxicity management for anti-tumor activity of cars | |
| HK40069741A (en) | Toxicity management for anti-tumor activity of cars | |
| HK40039113A (en) | Toxicity management for anti-tumor activity of cars | |
| Hanna | Integrating Immunotherapy With Chemoradiation in the Treatment of Head and Neck Cancer |